ArticleEuropean journal of medical research2025
Molecular subtype-driven disparities in intraoperative touch imprint cytology accuracy for sentinel lymph node assessment in clinically node-positive breast cancer treated with neoadjuvant chemotherapy.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study aimed to investigate the impact of molecular subtype on the accuracy of intraoperative touch imprint cytology (ITPC) for sentinel lymph node (SLN) evaluation in clinically axillary node-positive (cN +) breast cancer patients treated with neoadjuvant chemotherapy (NAC).
methodsWe conducted a retrospective cohort study of 232 cN + breast cancer patients undergoing NAC followed by SLN biopsy with ITPC. Diagnostic performance values (sensitivity, specificity, NPV, false-negative rate, etc.) were calculated against final histopathological diagnosis, and stratified by molecular subtypes.
resultsITPC identified 53 positive cases (23 false-negatives) across 917 SLNs, demonstrating 69.74% sensitivity, 100% specificity, and 87.15% NPV. HER2-positive (nonluminal) tumors showed the highest tpCR (67.53%) with a moderate SLN-positive rate (24.14%) and the lowest false-negative rate (3.90%). Luminal B (HER2-positive) tumors exhibited a moderate tpCR (57.89%) and a SLN-positive rate (29.31%) but a higher false-negative rate (13.79%). In contrast, both Luminal A and Luminal B HER2-negative displayed lower tpCRs (0.00% and 20.00%), higher SLN-positive rates (66.67% and 57.78%), and higher false-negative rates (33.33% and 22.22%). Notably, TNBC showed a tpCR of 48.98%, a SLN-positive rate of 34.69%, and the lowest false-negative rate of 2.04%. Chemotherapy-induced changes in SLNs (OR = 11.155, 95% CI 2.002-62.152; p = 0.006) and residual micrometastases/ITCs (OR = 37.843, 95% CI 5.031-284.671; p < 0.0001) were independent influencing factors of false-negative results.
conclusionsCollectively, our study demonstrates that ITPC exhibits a robust accuracy for detecting SLN metastases in cN + breast cancer patients treated with NAC. The findings support the implementation of molecular subtype-specific SLN management: ITPC alone may be adequate for HER2-positive and TNBC tumors; for hormone receptor-positive (Luminal) subtypes, ITPC may need to be combined with molecular/immunohistochemical analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.